CAJ | 학술논문

目的：评估细胞因子诱导的杀伤细胞( cytokine-induced killer cells, CIK)治疗中晚期泌尿生殖系统肿瘤的效果。方法对成都军区昆明总医院2005年6月—2010年2月收治的仅接受过手术治疗的38例中晚期泌尿生殖系统肿瘤行CIK治疗,比较治疗前后机体免疫状态变化、疗效及毒性反应、肿瘤标志物及生活质量变化。结果2个疗程后,38例外周血免疫指标CD3+、CD56+、CD3+CD56+ T细胞百分率均较治疗前显著增高(P<0．05)；临床缓解率达94.7%；相关肿瘤标志物(癌胚抗原、癌抗原125、乳酸脱氢酶及前列腺特异性抗原)水平均较治疗前显著下降( P<0．01)；生存质量Karnofsky评分较治疗前平均提高10~20分,提高率为94.7%,平均体质量较治疗前增加1~2 kg。结论 CIK疗法为中晚期泌尿生殖系统肿瘤患者提供了一种可以延长生存期、提高生活质量的有效方法。
목적：평고세포인자유도적살상세포( cytokine-induced killer cells, CIK)치료중만기비뇨생식계통종류적효과。방법대성도군구곤명총의원2005년6월—2010년2월수치적부접수과수술치료적38례중만기비뇨생식계통종류행CIK치료,비교치료전후궤체면역상태변화、료효급독성반응、종류표지물급생활질량변화。결과2개료정후,38예외주혈면역지표CD3+、CD56+、CD3+CD56+ T세포백분솔균교치료전현저증고(P<0．05)；림상완해솔체94.7%；상관종류표지물(암배항원、암항원125、유산탈경매급전렬선특이성항원)수평균교치료전현저하강( P<0．01)；생존질량Karnofsky평분교치료전평균제고10~20분,제고솔위94.7%,평균체질량교치료전증가1~2 kg。결론 CIK요법위중만기비뇨생식계통종류환자제공료일충가이연장생존기、제고생활질량적유효방법。
Objective To investigate the clinical curative effect of cytokine-induced killer cells (CIK) in treatment of middle-late stage of urogenital neoplasms. Methods A total of 38 middle-late stage of urogenital neoplasms patients, who un-derwent only surgical treatment, were treated with CIK therapy during June 2005 and February 2010, and the changes of body's immune status, clinical effect and toxic reaction, tumor markers, and the changes of quality of life were compared before and after the treatment. Results After two courses of treatment for the 38 patients, peripheral blood of immune parameters CD3+, CD56+ and CD3+ CD56+ T cell percentages were significantly higher than those before treatment (P<0. 05);clinical remis-sion rate was 94. 7%;related levels of tumor markers [carcinoembryonic antigen (CEA), cancer antigen 125, lactate dehydro-genase, prostate-specific antigen)] were significantly decreased after treatment compared with those before treatment (P<0. 01). Karnofsky score for quality of life after treatment was increased at an average of 10 to 20 points compared with that be-fore treatment, and the increase rate was 94. 7%, and average body mass after treatment increased 1-2 kg. Conclusion CIK therapy in treatment of middle-late stage of urogenital neoplasms may prolong life span and improve the quality of life.